Butterfly Network's shares rallied dramatically in morning trading after Midjourney, known for its AI image-generation tools, announced a new healthcare arm called Midjourney Medical and introduced the Midjourney Scanner - a full-body ultrasonic computational tomography system that relies on Butterfly's licensed Ultrasound-on-Chip semiconductor technology.
According to a Butterfly press release, the current prototype integrates 40 of Butterfly's imaging modules per system. The companies said future generations are expected to employ substantially more modules. The collaboration is structured as a co-development agreement that carries up to $74 million in expected payments.
Market participants quickly interpreted the announcement as a signal that Butterfly's underlying semiconductor platform has value beyond its established handheld ultrasound products. TD Cowen analyst Joshua Jennings told investors that the unveiling highlights the often-overlooked potential of Butterfly's chip architecture, arguing that the tie-up validates Butterfly Embedded as a licensable semiconductor infrastructure able to produce licensing revenue, future chip sales, and revenue sharing.
Investor focus was intensified by scheduled management exposure: Butterfly's CEO Joe DeVivo, CFO John Doherty, and SVP of Innovation David Horsley were due to speak at a TD Cowen Medical Devices Emerging Growth Call at noon ET, keeping attention on the name throughout the session.
Short interest ahead of the announcement was notable, representing approximately 12.6% of the float. That positioning amplified the stock's upward move as bearish positions were unwound during the session.
The broader market backdrop was supportive of risk assets. The S&P 500 gained +0.9% and the Nasdaq climbed +1.2% during the session, a tone that tended to favor growth-oriented healthcare and device names. Butterfly shares reached a session high of $8.01, which the company noted as a new 52-week high, reflecting the scale of the company-specific catalyst relative to the sector.
Measured against the prior close of $5.71, the confluence of a high-profile partnership announcement, analyst validation of a chip-licensing strategy, and a scheduled management call drove the stock to its highest level in over a year and pushed it past the prior 52-week threshold cited during the session.
What moved the stock
- Confirmation that Midjourney's new medical scanner is built on Butterfly's licensed Ultrasound-on-Chip technology.
- Disclosure that the prototype contains 40 imaging modules and that later versions are expected to use substantially more modules under a co-development agreement with up to $74 million in expected payments.
- Analyst commentary from TD Cowen emphasizing the value of Butterfly's chip platform as a licensable infrastructure, plus a management appearance at a sector-focused investor call.
The interaction of those elements produced a sharp intra-session rally, which was further magnified by the presence of meaningful short interest in the stock.